02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
20:30 , Oct 29, 2018 |  BC Extra  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
22:26 , May 18, 2017 |  BC Innovations  |  Targets & Mechanisms

Degrading NASH

Inflammation is one of the primary drivers of non-alcoholic steatohepatitis (NASH), but decreasing inflammation without creating susceptibility to infection remains a challenge for the field. In Nature Medicine this month, a Chinese team described how...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Diacylglycerol O-acyltransferase-2 (DGAT2)

Endocrine/metabolic disease INDICATION: Dyslipidemia In vitro and mouse studies identified a DGAT2 inhibitor that could help treat dyslipidemia and other metabolic disorders. Screening of a small molecule library in enzymatic assays and optimization of hits...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Diacylglycerol O-acyltransferase-2 (DGAT2)

Endocrine/metabolic disease INDICATION: Hypercholesterolemia In vitro and mouse studies identified a DGAT2 inhibitor that could help treat hypercholesterolemia. Chemical synthesis and testing in DGAT2 activity assays of imidazopyridine analogs identified a compound that inhibited DGAT2...
07:00 , Oct 28, 2010 |  BC Innovations  |  Cover Story

DGAT out of the bag

U.S. and French researchers have shown that DGAT1 , an enzyme involved in lipid droplet biogenesis, is a host factor for HCV infection. 1 The results have prompted Via Pharmaceuticals Inc. to consider repurposing its...